Richard J Kim
CIK 1705154 · Chief Commercial Officer · last filed 2024-03-04
Richard J Kim is a Chief Commercial Officer who has filed 24 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing, for AVDL, was dated Mar 4, 2024. Across all open-market trades the lifetime net is −$20.3K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
24
-$20.3K
Filer Profile
WEST WINDSOR, NJ 08550
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Chief Commercial Officer | — | $21.64 | — | $0 | 4 | 2024-03-04 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | President US Comm & Strat Mktg | 20,029 | $19.00 | $380.6K | -$20.3K | 20 | 2021-01-05 |
Recent Filings
24 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-03-04 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-05 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-12-09 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-02-17 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-05 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Tax (F) | −1,058 | -$26.1K | EDGAR |
| 2020-10-05 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Tax (F) | −223 | -$9.4K | EDGAR |
| 2020-07-06 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Tax (F) | −224 | -$10.4K | EDGAR |
| 2020-04-03 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Tax (F) | −223 | -$13.0K | EDGAR |
| 2020-01-27 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Grant (A) | +5,400 | $0 | EDGAR |
| 2020-01-03 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Tax (F) | −649 | -$80.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.